Results: During processing of our patient's data, we found certain relation between segmented neutrophils, monocytes, platelet count, total bilirubin and the degree of esophageal varices for the detection of high risk varices and a new equation was formulated and we called it P2/MS-B. In predicting high risk esophageal varices HREV, the area under the curve for this new variable was [0.909, 95% confidence interval 0.858 -0.961, p = 0.000] which was significantly higher than all the other variables including P2/MS for the detection of HREV. The sensitivity of the new equation for the detection of HREV is 85.3%, the specificity is 83.1%, the positive predictive value is 87.9%, the negative predicative value is 86.0 % and the overall accuracy of the test is 85.6%. Conclusion: A newly detected noninvasive variable for detecting HREV may reliably screen liver cirrhosis patients for HREV and avoid unnecessary endoscopy in low risk patients.
Introduction
Portal hypertension is a progressive complication of liver cirrhosis and it is the cause of high morbidity and mortality. Gastroesophageal varices are present in approximately 50% of patients with cirrhosis. The management of cirrhotic patients with varices differs according to the grade of varices or the presence of acute variceal bleeding. While varices are found in 40% of Child A patients, they can be present in up to 85% of Child C patients [1] . Cirrhotic patients develop varices at a rate of 8% per year and the strongest predictor for their development in those who have no varices at the time of initial endoscopic screening is a portal-hepatic venous pressure gradient (HVPG) more than 10 mmHg [2] [3] . Variceal hemorrhage occurs at a yearly rate of 5% -15%, and its most important predictor is the size of varices, with the highest risk of first hemorrhage occurring in patients with large varices [4] .
The gold standard for the diagnosis of varices is esophagogastroduodenoscopy (EGD).
It is recommended that patients with cirrhosis undergo endoscopic screening for varices at the time of diagnosis [5] [6] . Since the point prevalence of medium/large varices is approximately 15% -25% [1] , the majority of subjects undergoing screening EGD either do not have varices or have varices that do not require prophylactic therapy. Thus, several models have been proposed to predict the presence of high risk varices by nonendoscopic methods and have excited considerable interest among researchers. Multiple studies have evaluated possible noninvasive markers of esophageal varices in patients with cirrhosis such as: the platelet count, Fibrotest, spleen size, portal vein diameter, and transient elastography [7] [8]. Lee and coworkers recently proposed a simple noninvasive test, P2/MS, which they developed in a study of patients with virusrelated chronic liver disease (CLD) [9] . They used the following formula: (platelet count) 2 /[monocyte fraction (%) − segmented neutrophil fraction (%)]. However, P2/MS has received little external validation of its diagnostic accuracy and cut-off values for detection of esophageal varices [10] . We, therefore, conducted the current study to externally validate P2/MS, to determine optimal thresholds to predict high risk esophageal varices (HREV) in patients with liver cirrhosis, and to compare results of the P2/MS index with those from other noninvasive tests.
Patients and Methods

Patients
Between August 2010 and May 2011, we prospectively enrolled 125 consecutive patients with liver cirrhosis presenting for routine follow up of their condition at Internal Medicine Department Kasr El-Aini Hospital. Cirrhosis was diagnosed clinically by history and physical examination, as well as by standard laboratory and sonographic data. The exclusion criteria included the following: the presence of infection or fever; alcohol ingestion in excess of 30 g/day for more than 45 years; previous variceal bleeding; beta-blocker therapy; previous endoscopic treatments (bandligation or sclerotherapy); previous surgery forportal hypertension or Transjugular Intrahepatic Portosystemics-tent shunt placement; portal vein orsplenic vein thrombosis and Hepatocellular Carcinoma. All subjects received complete biochemical evaluations, ultrasonography and endoscopy within 2 days of admission. The study protocol followed the ethical guidelines of the 1975 Declaration of Helsinki. We obtained written, informed consent from each participant or a responsible family member after fully explaining the possible complications of the diagnostic procedures. The Institutional ethical committee approved this study.
P2/MS, and Other Noninvasive Tests
For the calculation of noninvasive tests including P2/MS, the laboratory data obtained on the same day as the endoscopic examination were used. Within one day following or preceding the endoscopy, all patients underwent an ultrasonographic examination of the upper abdomen, performed by an experienced operator blinded to the patients' clinical and laboratory data. A spleen bipolar diameter was defined as the greatest longitudinal dimension at the level of splenic hilum on the image monitor using electronic calipers [11] .
The values for P2/MS and other noninvasive tests were calculated automatically, using previously published data ( 
Endoscopic Evaluation
Statistical Analysis
The goals of this study were to validate the diagnostic value of P2/MS for the detection of esophageal varices and to estimate optimal P2/MS cut-off points to indicate when a patient with liver cirrhosis should undergo prophylactic treatment. To assess the diagnostic accuracy of each noninvasive index, receiver operating characteristic [ROC] curves were constructed and the corresponding areas under the ROC curve [AUROC] were computed. The data was coded and entered using the statistical package SPSS ver- 
Results
Patient Characteristics
The mean age of the patients [86 males, 39 females] was 55.17 ± 7.73 years ( [16] were 0.573 [95% CI 0.471 -0.675], all of which were significantly lower than that of P2/MS (Table 3 ).
During processing of our patients' data and on doing bivariate analysis, we found a certain relation between segmented neutrophil, monocytes, platelet count and total bilirubin in detection of HREV, so we entered those variables in a logistic regression model and found data depicted in Table 4 from which we obtained a new formula for predicting HREV. We named this formula P2/MS-B. Accordingly, a probability score was calculated for each patient, and then we analyzed this score to the ROC curve to va- 
Determination of the Optimal Cut-Off Values
As the central goal of this study, we sought to validate the noninvasive P2/MS test as a Figure 1 & Figure 2 ).
The cut off points for the other variables showed lower sensitivity and specificity compared to P2/MS or the new test variable P2/MS-B. Compared to other cut off values, the new variable was the only test that showed better accuracy in detecting HREV.
At a cut-off value of 0.5743, high risk esophageal varices were found when the numbers were greater than or equal to this number. The new test achieved a PPV of 87.9 %, a sensitivity of 85.3%, a specificity of 83.1%, a NPV of 86.0% and a total accuracy of 85.6%.
Discussion
Current guidelines recommend periodic endoscopic screening to all cirrhotic patients A new index, P2/MS, based on a complete blood count, is specifically designed to predict esophageal varices in chronic liver disease. We conducted validation of the P2/MS index, and can now suggest optimal cut-off points to predict the presence of HREVs in patients with liver cirrhosis. Our study, has shown that a combination of simple, non-invasive serum markers could avoid performing unnecessary endoscopies, with only a small number of misdiagnosed cases. 
Conclusion
P2/MS as well as P2/MS-B formulae are reliable means for detecting HREV. They are noninvasive, exhibit a high rate of accuracy and are cost effective.
Recommendation
Due to the small numbers of patients included in our study, reassessment of our new variable on a larger number of patients before validation is recommended.
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